SCHEMBL5370145

SCHEMBL5370145

CC(C)(C)c1cc(C=C2C(=O)Nc3ccc(CCCl)cc32)ccc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.56
EGFR P00533 3/20 0.56
PPARG P37231 2/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
IGF1R P08069 1/20 0.45
PSEN1 P49768 5/20 0.43
PSEN2 P49810 5/20 0.43
APH1B Q8WW43 5/20 0.43
NCSTN Q92542 5/20 0.43
APH1A Q96BI3 5/20 0.43
PSENEN Q9NZ42 5/20 0.43
GSK3B P49841 1/20 0.42
HPGD P15428 1/20 0.42
LRRK2 Q5S007 1/20 0.42
PTPN1 P18031 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358637 0.89 ERBB2 (0.51) ERBB2EGFRPPARGSIRT2IGF1R
SCHEMBL5364127 0.88 ERBB2 (0.73) ERBB2EGFRIGF1RPSEN1PSEN2
SCHEMBL5376624 0.86 ERBB2 (0.50) ERBB2EGFRPPARGIGF1RPSEN1
SCHEMBL5370370 0.85 ERBB2 (0.58) ERBB2EGFRSIRT2IGF1RPSEN1
SCHEMBL5358813 0.85 ERBB2 (0.47) ERBB2EGFRPPARGSIRT2IGF1R
SCHEMBL7139020 0.83 PSEN1 (0.61) PPARGSIRT2PSEN1PSEN2APH1B
SCHEMBL5361587 0.82 ERBB2 (0.53) ERBB2EGFRIGF1RPSEN1PSEN2
SCHEMBL5363020 0.81 ERBB2 (0.54) ERBB2EGFRPPARGSIRT2IGF1R
SCHEMBL7138836 0.81 MAOA (0.51) PPARGSIRT2PSEN1PSEN2APH1B
SCHEMBL5367600 0.80 LRRK2 (0.53) PPARGSIRT2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885PPARG 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.